BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37090107)

  • 21. FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma.
    Wu Q; Shao T; Huang G; Zheng Z; Jiang Y; Zeng W; Lv X
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291667
    [No Abstract]   [Full Text] [Related]  

  • 22. IGF2BP2 serves as a core m6A regulator in head and neck squamous cell carcinoma.
    Hu Y; Chen J; Liu M; Feng Q; Peng H
    Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRIB3, as a robust prognostic biomarker for HNSC, is associated with poor immune infiltration and cancer cell immune evasion.
    Wu H; Fu Z; Li H; Fang F; He B; Ye Y; Wu H; Xu D; Zheng H; Zhang Q
    Front Immunol; 2023; 14():1290839. PubMed ID: 38235126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homeobox-D 1 and FTO form a transcriptional-epigenetic feedback loop to promote head and neck cancer proliferation.
    Zhang C; Xie L; Lin Z
    Cell Biol Int; 2023 Dec; 47(12):1987-1998. PubMed ID: 37655555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Gene-Tyrosine Kinase 2 (TYK2) in Head and Neck Squamous Cell Carcinoma Patients-An Integrated Bioinformatics Approach.
    Gong X; Ren F
    Dis Markers; 2022; 2022():5239033. PubMed ID: 35711568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of XRCC1 is Associated with Poor Survival in Patients with Head and Neck Squamous Carcinoma and Has Potential to Be Used as Targeted Therapy by Synthetic Lethality.
    Ahirwar SS; Lasunte S; Gupta M; Chowdhary R; Kotnis A
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3525-3535. PubMed ID: 37898859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and prognostic analysis of BGN in head and neck squamous cell carcinoma.
    Zhao L; Liang J; Zhong W; Han C; Liu D; Chen X
    Gene; 2022 Jun; 827():146461. PubMed ID: 35358652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pan-cancer analysis reveals the pro-oncogenic role of N6-methyladenosine (m6A)-regulated NTMT1 in head and neck squamous cell carcinoma.
    Zhao C; Yu M; Li Y
    J Biochem Mol Toxicol; 2024 Jan; 38(1):e23603. PubMed ID: 38014887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma (HNSC) for the Exploration of Immunotherapy and Prognosis.
    Huang C; Liu J
    Genet Res (Camb); 2022; 2022():6880760. PubMed ID: 36636556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Biological function and clinical significance of long non-coding RNA
    Dong YY; Zheng XW; Mijiti M; Tian R; Guo QB; Wu YY; Gao W; Wen SX
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Mar; 58(3):240-249. PubMed ID: 36878503
    [No Abstract]   [Full Text] [Related]  

  • 31. An integrative analysis of enhancer of yellow 2 homolog (ENY2) as a molecular biomarker in pan-cancer.
    Chen Q; Shi X; Bao Y; Sun G; Wu S; Chen Y
    Funct Integr Genomics; 2023 Mar; 23(1):72. PubMed ID: 36862319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP4F12 is a potential biomarker and inhibits cell migration of head and neck squamous cell carcinoma via EMT pathway.
    Jia W; Chen S; Wei R; Yang X; Zhang M; Qian Y; Liu H; Lei D
    Sci Rep; 2023 Jul; 13(1):10956. PubMed ID: 37414830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
    Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
    Front Immunol; 2022; 13():975847. PubMed ID: 36091055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profiles of immune cell infiltration in head and neck squamous carcinoma.
    Liang B; Tao Y; Wang T
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32095823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of
    Yao YF; Liu W; Zhou ML; Qiu TL; Wang K
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 May; 53(3):457-465. PubMed ID: 35642155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FSCN1 is upregulated by SNAI2 and promotes epithelial to mesenchymal transition in head and neck squamous cell carcinoma.
    Wang L; Jia Y; Jiang Z; Gao W; Wang B
    Cell Biol Int; 2017 Aug; 41(8):833-841. PubMed ID: 28488774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA splicing regulator EIF3D regulates the tumor microenvironment through immunogene-related alternative splicing in head and neck squamous cell carcinoma.
    Lu D; Mihoayi M; Ablikim Y; Arikin A
    Aging (Albany NY); 2024 Mar; 16(7):5929-5948. PubMed ID: 38535990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NUTF2 as a Prognostic Indicator and Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Li P; Wen X; Zhang X; Wang F; Zhang D; Shang H
    Genet Test Mol Biomarkers; 2022 Dec; 26(12):553-563. PubMed ID: 36577127
    [No Abstract]   [Full Text] [Related]  

  • 39. Syntenin-1 is a promoter and prognostic marker of head and neck squamous cell carcinoma invasion and metastasis.
    Cui L; Cheng S; Liu X; Messadi D; Yang Y; Hu S
    Oncotarget; 2016 Dec; 7(50):82634-82647. PubMed ID: 27811365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LINC01614 is a promising diagnostic and prognostic marker in HNSC linked to the tumor microenvironment and oncogenic function.
    Tian X; Hu D; Wang N; Zhang L; Wang X
    Front Genet; 2024; 15():1337525. PubMed ID: 38655053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.